Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
| العنوان: | Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia |
|---|---|
| المؤلفون: | Nivritti Gajanan Patil, Brian Tomlinson, Christopher W.K. Lam, Manson Fok |
| المصدر: | Endocrinology and Metabolism, Vol 36, Iss 2, Pp 279-295 (2021) Endocrinology and Metabolism |
| بيانات النشر: | Korean Endocrine Society, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Statin, medicine.drug_class, Endocrinology, Diabetes and Metabolism, hydroxymethylglutaryl-coa reductase inhibitors, hyperlipoproteinemia type ii, alirocumab, Review Article, Familial hypercholesterolemia, Pharmacology, Diseases of the endocrine glands. Clinical endocrinology, Subcutaneous injection, Endocrinology, Ezetimibe, medicine, Humans, rna, human, small interfering, Alirocumab, pcsk9 protein, business.industry, PCSK9, PCSK9 Inhibitors, Cholesterol, LDL, RC648-665, Proprotein convertase, medicine.disease, Evolocumab, evolocumab, lipids (amino acids, peptides, and proteins), Proprotein Convertase 9, business, medicine.drug |
| الوصف: | Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require additional lipid-modifying therapies. Drugs that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) offer a novel approach to reduce LDL-C. The monoclonal antibodies, alirocumab and evolocumab, given by subcutaneous injection every 2 or 4 weeks produce reductions in LDL-C of 50% to 60% in patients with HeFH, allowing many of them to achieve their LDL-C goals. Patients with HoFH show a reduced and more variable LDL-C response, which appears to depend on residual LDL receptor activity, and those with receptor-negative mutations may show no response. Inclisiran is a long-acting small interfering RNA therapeutic agent that inhibits the synthesis of PCSK9. Subcutaneous doses of 300 mg can reduce LDL-C by more than 50% for at least 6 months and the responses in HeFH and HoFH patients are similar to those achieved with monoclonal antibodies. These PCSK9 inhibitors are generally well tolerated and they provide a new opportunity for effective treatment for the majority of patients with FH. |
| تدمد: | 2093-5978 2093-596X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b7d588d7d38f9a0ac7d34288e95ff9Test https://doi.org/10.3803/enm.2021.964Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a7b7d588d7d38f9a0ac7d34288e95ff9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20935978 2093596X |
|---|